Avelox 1,6 mg/ml infusionsvæske, opløsning Danimarca - danese - Lægemiddelstyrelsen (Danish Medicines Agency)

avelox 1,6 mg/ml infusionsvæske, opløsning

bayer ab - moxifloxacinhydrochlorid - infusionsvæske, opløsning - 1,6 mg/ml

Doxorubicin "Ebewe" 2 mg/ml injektionsvæske, opløsning Danimarca - danese - Lægemiddelstyrelsen (Danish Medicines Agency)

doxorubicin "ebewe" 2 mg/ml injektionsvæske, opløsning

ebewe pharma ges.m.b.h. nfg. kg - doxorubicinhydrochlorid - injektionsvæske, opløsning - 2 mg/ml

Glucose-Na-K Baxter 50 mg/ml infusionsvæske, opløsning Danimarca - danese - Lægemiddelstyrelsen (Danish Medicines Agency)

glucose-na-k baxter 50 mg/ml infusionsvæske, opløsning

baxter a/s - glucosemonohydrat, kaliumchlorid, magnesiumchloridhexahydrat, natriumacetattrihydrat, natriumchlorid - infusionsvæske, opløsning - 50 mg/ml

Cabometyx Unione Europea - danese - EMA (European Medicines Agency)

cabometyx

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastiske midler - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.

Alecensa Unione Europea - danese - EMA (European Medicines Agency)

alecensa

roche registration gmbh - alectinibhydrochlorid - carcinom, ikke-småcellet lunge - antineoplastiske midler - alecensa som monoterapi er indiceret til førstegangsbehandling af voksne patienter med anaplastisk lymfomkinase (alk) -positive avanceret ikke-småcellet lungecancer (nsclc). alecensa som monoterapi er indiceret til behandling af voksne patienter med alk‑positive avanceret nsclc, der tidligere er behandlet med crizotinib.